within Pharmacolibrary.Drugs.ATC.C;

model C10AB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.02333333333333333,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.00029,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0023333333333333335,
    Tlag           = 1200
  );

  annotation(Documentation(
    info ="<html><body><p>Clofibrate is a fibrate drug previously used as a lipid-lowering agent for the treatment of hyperlipidemia and to reduce cholesterol and triglyceride levels. It acts as a peroxisome proliferator-activated receptor (PPAR) agonist. Clofibrate is largely discontinued or withdrawn in many countries due to safety concerns and limited efficacy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dose.</p><h4>References</h4><ol><li><p>Duan, C, Cheng, W, Chen, Q, Li, X, &amp; Zhang, J (2021). Pharmacokinetics and tissue distribution of cantharidin after oral administration of aqueous extracts from Mylabris in rats. <i>Biomedical chromatography : BMC</i> 35(10) e5172–None. DOI:<a href=&quot;https://doi.org/10.1002/bmc.5172&quot;>10.1002/bmc.5172</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33982312/&quot;>https://pubmed.ncbi.nlm.nih.gov/33982312</a></p></li><li><p>Crouthamel, WG, &amp; Cenedella, RJ (1975). Clofibrate pharmacokinetics: effect of elevation of plasma-free fatty acids. <i>Pharmacology</i> 13(5) 465–473. DOI:<a href=&quot;https://doi.org/10.1159/000136939&quot;>10.1159/000136939</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1208648/&quot;>https://pubmed.ncbi.nlm.nih.gov/1208648</a></p></li><li><p>Houin, G, Thébault, JJ, D&#x27;Athis, P, Tillement, JP, &amp; Beaumont, JL (1975). A GLC method for estimation of chlorophenoxyisobutyric acid in plasma. Pharmacokinetics of a single oral dose of clofibrate in man. <i>European journal of clinical pharmacology</i> 8(6) 433–437. DOI:<a href=&quot;https://doi.org/10.1007/BF00562318&quot;>10.1007/BF00562318</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1233245/&quot;>https://pubmed.ncbi.nlm.nih.gov/1233245</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C10AB01;
